These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15333967)

  • 41. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
    J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
    Raal FJ; Marais AD; Klepack E; Lovalvo J; McLain R; Heinonen T
    Atherosclerosis; 2003 Dec; 171(2):273-9. PubMed ID: 14644397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of atorvastatin when not administered daily.
    Ghattas AE; Pimenta J
    Arq Bras Cardiol; 2007 Nov; 89(5):294-300, 325-32. PubMed ID: 18066453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
    Soedamah-Muthu SS; Colhoun HM; Thomason MJ; Betteridge DJ; Durrington PN; Hitman GA; Fuller JH; Julier K; Mackness MI; Neil HA;
    Atherosclerosis; 2003 Apr; 167(2):243-55. PubMed ID: 12818407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effects of atorvastatin on hyperlipidemia in kidney disease patients].
    Kawamoto S; Kawamura T; Miyazaki Y; Hosoya T
    Nihon Jinzo Gakkai Shi; 2007; 49(1):41-8. PubMed ID: 17299985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
    Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
    Karalis DG; Ross AM; Vacari RM; Zarren H; Scott R
    Am J Cardiol; 2002 Mar; 89(6):667-71. PubMed ID: 11897207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
    Simons LA
    Aust N Z J Med; 1998 Jun; 28(3):327-33. PubMed ID: 9673745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The hepatoprotective effect of the combination use of Fructus Schisandrae with statin--A preclinical evaluation.
    Wat E; Ng CF; Wong EC; Koon CM; Lau CP; Cheung DW; Fung KP; Lau CB; Leung PC
    J Ethnopharmacol; 2016 Feb; 178():104-14. PubMed ID: 26666731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
    Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A
    J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dosing of atorvastatin and increases in fibrinogen level.
    Sinzinger H; Rodrigues M; Furberg CD
    Atherosclerosis; 1999 Dec; 147(2):421-2. PubMed ID: 10627270
    [No Abstract]   [Full Text] [Related]  

  • 56. [Effect of various approaches to therapy with statins in high risk patients from the point of view of vascular endothelium].
    Kulev BD; Ageev FT
    Kardiologiia; 2009; 49(5):4-10. PubMed ID: 19463127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
    Orem C; Orem A; Calapoğlu M; Baykan M; Uydu HA; Erdöl C
    Acta Cardiol; 2002 Dec; 57(6):421-5. PubMed ID: 12542120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
    Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
    Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E; Harats D; Gavish D
    Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.